Cargando…

Impact of the Addition of Baricitinib to Standard of Care Including Tocilizumab and Corticosteroids on Mortality and Safety in Severe COVID-19

Background: Baricitinib is a Janus kinase (JAK) inhibitor with a broader anti-inflammatory activity than tocilizumab and an antiviral potential although no head-to-head trials are available. The benefits of adding baricitinib to patients with COVID-19 experiencing clinical progression despite the st...

Descripción completa

Detalles Bibliográficos
Autores principales:	Masiá, Mar, Padilla, Sergio, García, José Alberto, García-Abellán, Javier, Navarro, Andrés, Guillén, Lucía, Telenti, Guillermo, Mascarell, Paula, Botella, Ángela, Gutiérrez, Félix
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2021
Materias:	Medicine
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8606519/ https://www.ncbi.nlm.nih.gov/pubmed/34820393 http://dx.doi.org/10.3389/fmed.2021.749657

Ejemplares similares

Impact of interleukin-6 blockade with tocilizumab on SARS-CoV-2 viral kinetics and antibody responses in patients with COVID-19: A prospective cohort study
por: Masiá, Mar, et al.
Publicado: (2020)

SARS-CoV-2 Seroconversion and Viral Clearance in Patients Hospitalized With COVID-19: Viral Load Predicts Antibody Response
por: Masiá, Mar, et al.
Publicado: (2021)

Preemptive interleukin-6 blockade in patients with COVID-19
por: Guillén, Lucía, et al.
Publicado: (2020)

Dyspnea and pleuritic chest pain during the COVID-19 pandemic
por: Guillén, Lucía, et al.
Publicado: (2021)

Dyspnea and pleuritic chest pain during the COVID-19 pandemic
por: Guillén, Lucía, et al.
Publicado: (2021)

Robust long-term immunity to SARS-CoV-2 in patients recovered from severe COVID-19 after interleukin-6 blockade
por: Masiá, Mar, et al.
Publicado: (2022)

Predictive factors for cardiac conduction abnormalities with hydroxychloroquine-containing combinations for COVID-19
por: Padilla, Sergio, et al.
Publicado: (2020)

Pericarditis caused by Mycobacterium africanum: case report
por: Mascarell, Paula, et al.
Publicado: (2022)

Short-term Increase in Risk of Overweight and Concomitant Systolic Blood Pressure Elevation in Treatment-Naïve Persons Starting INSTI-Based Antiretroviral Therapy
por: Galdamez, Ronald, et al.
Publicado: (2019)

Durable antibody response one year after hospitalization for COVID-19: A longitudinal cohort study
por: Masiá, Mar, et al.
Publicado: (2021)

Late reinfection with a different severe acute respiratory syndrome coronavirus-2 clade in a patient with refractory arterial hypertension: a case report
por: García-Abellán, Javier, et al.
Publicado: (2021)

Lack of detrimental effect of corticosteroids on antibody responses to SARS-CoV-2 and viral clearance in patients hospitalized with COVID-19
por: Masiá, Mar, et al.
Publicado: (2021)

Effect of tocilizumab, sarilumab, and baricitinib on mortality among patients hospitalized for COVID-19 treated with corticosteroids: a systematic review and meta-analysis
por: Albuquerque, Arthur M., et al.
Publicado: (2023)

Tocilizumab, netakimab, and baricitinib in patients with mild-to-moderate COVID-19: An observational study
por: Bryushkova, Ekaterina A., et al.
Publicado: (2022)

Risk of hepatitis B reactivation following baricitinib or tocilizumab for treatment of COVID-19
por: Foo, Hong, et al.
Publicado: (2023)

2648. Taming the Cytokine Storm: Baricitinib versus Tocilizumab for COVID-19 Hyperinflammation
por: Radziszewski, Skyler, et al.
Publicado: (2023)

513. Evaluating the safety of baricitinib versus tocilizumab in hospitalized patients with COVID-19
por: Brickel, Kendall, et al.
Publicado: (2023)

509. A Comparison of Tocilizumab and Baricitinib for Hospitalized Patients with Severe COVID-19
por: Aytoda, Priyanka, et al.
Publicado: (2023)

Date of Admission during COVID-19 Pandemic Impacted Patient Outcomes in Addition to the Higher Efficacy of Tocilizumab Plus High-Dose Corticosteroid Therapy Compared to Tocilizumab Alone
por: Belhassen-García, Moncef, et al.
Publicado: (2021)

The Use of Corticosteroids or Tocilizumab in COVID-19 Based on Inflammatory Markers
por: Rubio-Rivas, Manuel, et al.
Publicado: (2021)

Comparative Efficacy of Tocilizumab and Baricitinib Administration in COVID-19 Treatment: A Retrospective Cohort Study
por: Kojima, Yuichi, et al.
Publicado: (2022)

Candidemia in COVID‐19 treated with corticosteroids and tocilizumab
por: Yamamoto, Koichiro, et al.
Publicado: (2021)

Tocilizumab versus baricitinib in hospitalized patients with severe COVID-19: an open label, randomized controlled trial
por: Karampitsakos, Theodoros, et al.
Publicado: (2023)

Combination therapy with tocilizumab and corticosteroids for aged patients with severe COVID-19 pneumonia: A single-center retrospective study
por: López-Medrano, Francisco, et al.
Publicado: (2021)

Combined administration of inhaled DNase, baricitinib and tocilizumab as rescue treatment in COVID-19 patients with severe respiratory failure
por: Gavriilidis, Efstratios, et al.
Publicado: (2022)

Tocilizumab Versus Baricitinib in Patients Hospitalized With COVID-19 Pneumonia and Hypoxemia: A Multicenter Retrospective Cohort Study
por: Roddy, John, et al.
Publicado: (2022)

Tocilizumab vs. baricitinib in hospitalized severe COVID-19 patients: results from a real-world cohort
por: Karolyi, Mario, et al.
Publicado: (2022)

Safety and Efficacy of Baricitinib in Patients Receiving Conventional Synthetic Disease-Modifying Antirheumatic Drugs or Corticosteroids
por: van Vollenhoven, Ronald, et al.
Publicado: (2018)

Immunologic phenotype of patients with long-COVID syndrome of 1-year duration
por: García-Abellán, Javier, et al.
Publicado: (2022)

Severe Adult-onset Still Disease with Constrictive Pericarditis and Pleuritis That Was Successfully Treated with Tocilizumab in Addition to Corticosteroids and Cyclosporin A
por: Kawaguchi, Hoshimi, et al.
Publicado: (2017)

Initiation of Tocilizumab or Baricitinib Were Associated With Comparable Clinical Outcomes Among Patients Hospitalized With COVID-19 and Treated With Dexamethasone
por: Wong, Carlos K. H., et al.
Publicado: (2022)

Efficacy and safety of baricitinib and tocilizumab in hospitalized patients with COVID-19: A comparison using systematic review and meta-analysis
por: Cherian, Jerin Jose, et al.
Publicado: (2022)

Evolving understanding of cardiovascular, cerebrovascular and peripheral arterial disease in people living with HIV and role of novel biomarkers. A study of the Spanish CoRIS cohort, 2004-2015
por: Masiá, Mar, et al.
Publicado: (2019)

Tocilizumab in addition to standard of care in the management of COVID-19: a meta-analysis of RCTs
por: Mutua, Victor, et al.
Publicado: (2022)

Additional baricitinib loading dose improves clinical outcome in COVID-19
por: Hasan, Md Jahidul, et al.
Publicado: (2020)

Antibody Response to SARS-CoV-2 is Associated with Long-term Clinical Outcome in Patients with COVID-19: a Longitudinal Study
por: García-Abellán, Javier, et al.
Publicado: (2021)

The effects of combination-therapy of tocilizumab and baricitinib on the management of severe COVID-19 cases: a randomized open-label clinical trial
por: Dastan, Farzaneh, et al.
Publicado: (2023)

Baricitinib for patients with severe COVID-19—time to change the standard of care?
por: Supady, Alexander, et al.
Publicado: (2022)

Beneficial effect of corticosteroids in preventing mortality in patients receiving tocilizumab to treat severe COVID-19 illness
por: Rubio-Rivas, Manuel, et al.
Publicado: (2020)

Tocilizumab/unspecified corticosteroids: Spinal epidural abscess: 2 case report
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_2l44kt6vb46sru4plpmgrrehni